Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
The Lancet. Infectious Diseases|May 1, 2023
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trialAitana Juan-Giner, Maria L Namulwana, Derick Kimathi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 8, 2022
Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitroJames Nyagwange, Bernadette Kutima, Kennedy Mwai, et al.
Plos Medicine|May 13, 2022
Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: A cohort studyDoris K Nyamwaya, Mark Otiende, Lilian Mwango, et al.
Lancet (London, England)|January 10, 2021
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trialAitana Juan-Giner, Derick Kimathi, Kyra H Grantz, et al.
Wellcome Open Research|March 17, 2020
Congenital microcephaly unrelated to flavivirus exposure in coastal KenyaHellen C Barsosio, John N Gitonga, Henry K Karanja, et al.
The Lancet. Infectious Diseases|May 1, 2023
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trialDerick Kimathi, Aitana Juan-Giner, Benedict Orindi, et al.
Viruses|September 27, 2025
Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex AssayGerald Waweru, Ruth Nyakundi, Bernadette Kutima, et al.
BMJ Global Health|August 1, 2022
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in KenyaStacey Orangi, John Ojal, Samuel Pc Brand, et al.
The Lancet. Infectious Diseases|November 14, 2025
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trialZacchaeus Anywaine, Jennifer Serwanga, Abu-Baker Mustapher Ggayi, et al.
Wellcome Open Research|December 6, 2024
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational studyJohn Kimotho, Yiakon Sein, Shahin Sayed, et al.
Pageof 7